Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Pharma Pursues Generic Injectables Quality Turnaround Opportunities

This article was originally published in The Gold Sheet

Executive Summary

Pfizer’s plan to acquire Hospira is part of a turnaround trend in which Big Pharma hopes its quality will rub off on the troubled generics injectables sector. The question is: Will it work?

You may also be interested in...



Pfizer/Mylan: Pending Clash Of Quality Systems Could Determine Fate Of New Firm

After years of Mylan’s “one quality standard,” the merger with Pfizer Upjohn brings another. Which will prevail? Which should prevail?

Pfizer Pauses To Remedy Quality At Irungattukottai Plant

A more effective approach to quality assurance could result from an operational pause at a Pfizer plant in India, where the company is responding to US FDA inspectional observations of poor data integrity and inadequate investigations that are expected to result in a warning letter.

The Baxter/Claris Warning Letter: Out Of Spec, Out Of Mind

US FDA's inspection found a major problem in the operations of the facility that became Baxter’s when it acquired Claris: staff were blaming the laboratory for out-of-specification test results when they should have been fixing the manufacturing process. The result: a warning letter packed with assignments for the new owners.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS000908

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel